[{"id":"7114fae7-0419-4c0e-a010-ae5f4d1c710b","acronym":"AEWS1221","url":"https://clinicaltrials.gov/study/NCT02306161","created_at":"2023-11-28T02:14:27.984Z","updated_at":"2025-02-25T16:36:29.981Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","source_id_and_acronym":"NCT02306161 - AEWS1221","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • daunorubicin • ganitumab (AMG 479)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 312","initiation":"Initiation: 12/12/2014","start_date":" 12/12/2014","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 09/19/2025","study_completion_date":" 09/19/2025","last_update_posted":"2025-02-06"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"310e631e-b071-40b1-a519-01d9a5329dbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04129151","created_at":"2021-01-18T20:10:20.167Z","updated_at":"2024-07-02T16:35:55.610Z","phase":"Phase 2","brief_title":"Palbociclib + Ganitumab In Ewing Sarcoma","source_id_and_acronym":"NCT04129151","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CDK4 • EWSR1 • IGF1 • FLI1 • FUS","pipe":"","alterations":" ","tags":["CDK4 • EWSR1 • IGF1 • FLI1 • FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • ganitumab (AMG 479)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 12/05/2019","start_date":" 12/05/2019","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 12/15/2022","study_completion_date":" 12/15/2022","last_update_posted":"2023-02-14"},{"id":"1ef49231-d3c5-4d4a-8854-a2f058fce18c","acronym":"QUILT-2.018","url":"https://clinicaltrials.gov/study/NCT00813605","created_at":"2021-01-18T03:05:28.580Z","updated_at":"2024-07-02T16:37:28.176Z","phase":"Phase 2","brief_title":"QUILT-2.018: Safety \u0026 Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma","source_id_and_acronym":"NCT00813605 - QUILT-2.018","lead_sponsor":"NantCell, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • ganitumab (AMG 479) • conatumumab (AMG 655)"],"overall_status":"Completed","enrollment":" Enrollment 155","initiation":"Initiation: 03/01/2009","start_date":" 03/01/2009","primary_txt":" Primary completion: 01/01/2011","primary_completion_date":" 01/01/2011","study_txt":" Completion: 06/01/2012","study_completion_date":" 06/01/2012","last_update_posted":"2016-10-27"},{"id":"7eef9046-4c7e-4e85-9bab-93bd226a5a5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01473303","created_at":"2021-01-18T06:08:44.129Z","updated_at":"2024-07-02T16:37:30.996Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT01473303","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • ganitumab (AMG 479)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 08/01/2012","primary_completion_date":" 08/01/2012","study_txt":"","study_completion_date":"","last_update_posted":"2016-06-28"}]